Thrombotic microangiopathy associated with unusual viral sequences in HIV-1-positive patients

Nephrology Dialysis Transplantation

Volumn 19, Issue 5, 2004, Pages 1129-1135

  Jochimsen, Friederike ^a,b   Gruening, Wolfram ^a   Arnould, Thierry ^a   Segal, Mark S ^a   Kruskall, Margot S ^a   Colgrove Jr , Robert ^a   Walz, Gerd ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Human immunodeficiency virus; Thrombotic microangiopathy

Indexed keywords

ANTITHROMBOCYTIC AGENT; CD4 ANTIGEN; CREATININE; LACTATE DEHYDROGENASE; LAMIVUDINE; STAVUDINE; STEROID; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; ZIDOVUDINE;

ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ENDOTHELIUM CELL; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; MACROPHAGE; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS ISOLATION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BASE SEQUENCE; CELL LINE; DNA PRIMERS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 2442625448     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh085     Document Type: Article

References (21)

1. Badesha PS, Aklayen MG. Hemolytic uremic syndrome as a presenting form of HIV infection. Nephron 1996; 72: 472-475
2. Alpers CE. Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. Kidney Int 2003; 63: 385-396
3. del Arco A, Martinez MA, Pena JM et al. Thrombotic thrombocytic purpura associated with human immunodeficiency virus infection: demonstration of p24 antigen in endothelial cells. Clin Infect Dis 1993; 17: 360-363
4. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280: 1884-1888
5. Clapham PR, Reeves JD, Simmons G, Dejucq N, Hibbitts S, McKnight A. HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. Mol Membr Biol 1999; 16: 49-55
6. Mukhtar M, Harley S, Chen P et al. Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN. Virology 2002; 297: 78-88
7. Ullrich CK, Groopman JE, Ganju RK. HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood 2000; 96: 1438-1442
8. Yoshimura K, Matsushita S, Hayashi A, Takatsuki K. Relationship of HIV-1 envelope V2 and V3 sequences of the primary isolates to the viral phenotype. Microbiol Immunol 1996; 40: 277-287
9. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6: 315-324
10. Masciotra S, Owen SM, Rudolph D et al. Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS 2002; 16: 1887-1898
11. Fox DG, Balfe P, Palmer CP, May JC, Arnold C, McKeating JA. Length polymorphism within the second variable region of the human immunodeficiency virus type I envelope glycoprotein affects accessibility of the receptor binding site. J Virol 1997; 71: 759-765
12. Salzwedel K, Smith ED, Dey B, Berger EA. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 2000; 74: 326-333
13. Gervasoni C, Ridolfo AL, Vaccarezza M et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 2002; 35: 1534-1540
14. Fouchier RA, Broersen SM, Brouwer M et al. Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype. AIDS Res Hum Retroviruses 1995; 11: 1473-1478
15. Shioda T, Oka S, Xin X et al. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J Virol 1997; 71: 4871-4881
16. Schuitemaker H, Fouchier RA, Broersen S et al. Envelope V2 configuration and HIV-1 phenotype: clarification. Science 1995; 268: 115
17. Hu Q, Trent JO, Tomaras GD et al. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J Mol Biol 2000; 302: 359-375
18. Daar ES, Li XL, Moudigil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990; 87: 6574-6578
19. Koito A, Harrowe G, Levy JA, Cheng-Mayer C. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994; 68: 2253-2259
20. Pohlmann S, Soilleux EJ, Baribaud F et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci USA 2001; 98: 2670-2675
21. McKeating JA, Griffiths PD, Weiss RA. HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor. Nature 1990; 343: 659-661